• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    571.21 -37.28 (-6.13%)
    Delayed Quote Updated: 2:11 PM EST, Nov 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 291,096
    Open 608.29
    Bid (Size) 570.64 (40)
    Ask (Size) 571.78 (80)
    Prev. Close 608.49
    Today's Range 570.66 - 608.29
    52wk Range 430.02 - 614.23
    Shares Outstanding 44,891,523
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What United Therapeutics (UTHR) Said on Its Q3 Earnings Call ↗
    United Therapeutics (NASDAQ:UTHR) reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission... 
    Via MarketBeat
    Topics Earnings Supply Chain
    News headline image
    United Therapeutics (UTHR) Q3 2026 Earnings Call Transcript ↗
    Tyvaso DPI growth lifted revenue while R&D spending weighed on profit. 
    Via The Motley Fool
    Topics Earnings

    Performance

    52-Week Range 7.0% below 52-week high
    571.21
    430.0252W Low 614.2352W High
    1 Week 7.0% below 1-week high
    578.281W Low 614.231W High

    United Therapeutics Corporation - Common Stock (UTHR) traded between $430.02 and $614.23 over the past 52 weeks and last traded at $571.21, 7.0% below its 52-week high. Over the past week it ranged between $578.28 and $614.23.

    Past 12 Months
    -3.8%
    +6.5%
    +10.1%
    -4.3%
    +15.0%
    +30.6%
    1W -$22.33
    1M +$34.81
    3M +$52.20
    6M -$25.55
    YTD +$74.49
    1Y +$133.88

    UTHR was +30.6% over the past year, -4.3% over six months, +15.0% year to date, -3.8% in the last week.

    12 Months vs Market
    UTHR
    +30.6%
    DIA
    +9.3%
    SPY
    +8.7%
    QQQ
    +5.3%
    IWM
    +12.2%

    Over the past 12 months UTHR returned +30.6% versus DIA (Dow) +9.3%, SPY (S&P 500) +8.7%, QQQ (Nasdaq 100) +5.3% and IWM (Russell 2000) +12.2%.

    Volume & Liquidity 0.40× 3-mo avg
    Today 291,096 3-mo avg 722.2K
    1W
    563.0K
    1M
    684.4K
    3M
    722.2K
    6M
    610.4K
    YTD
    557.8K
    1Y
    540.5K

    UTHR most recently traded 291,096 shares against a 3-month average daily volume of 722.2K.

    More News

    Read More
    United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings ↗
    Via Chartmill
    News headline image
    United Therapeutics Announces Buydown of Ralinepag Royalty
    From United Therapeutics Corporation
    Via Business Wire
    United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price ↗
    Via Chartmill
    United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗
    Via Chartmill
    News headline image
    United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soars
    Via StockStory
    News headline image
    United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
    Via StockStory
    News headline image
    United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    2 healthcare stocks to keep an eye on and 1 that underwhelm
    Via StockStory
    News headline image
    United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Market-Beating Stocks for Long-Term Investors
    Via StockStory
    News headline image
    2 Cash-Producing Stocks on Our Watchlist and 1 We Avoid
    Via StockStory
    News headline image
    United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
    From United Therapeutics
    Via Business Wire
    News headline image
    3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
    Via StockStory
    News headline image
    Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
    Via StockStory
    Topics Intellectual Property
    News headline image
    1 Mid-Cap Stock to Research Further and 2 That Underwhelm
    Via StockStory
    News headline image
    United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
    From United Therapeutics
    Via Business Wire
    News headline image
    Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
    Via StockStory
    Topics Intellectual Property
    News headline image
    United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗
    Via MarketBeat
    News headline image
    Why United Therapeutics (UTHR) Shares Are Falling Today
    Via StockStory

    Frequently Asked Questions

    Is United Therapeutics Corporation - Common Stock publicly traded?
    Yes, United Therapeutics Corporation - Common Stock is publicly traded.
    What exchange does United Therapeutics Corporation - Common Stock trade on?
    United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for United Therapeutics Corporation - Common Stock?
    The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
    What is the current price of United Therapeutics Corporation - Common Stock?
    The current price of United Therapeutics Corporation - Common Stock is 571.21
    When was United Therapeutics Corporation - Common Stock last traded?
    The last trade of United Therapeutics Corporation - Common Stock was at 11/05/26 02:11 PM ET
    What is the market capitalization of United Therapeutics Corporation - Common Stock?
    The market capitalization of United Therapeutics Corporation - Common Stock is 25.64B
    How many shares of United Therapeutics Corporation - Common Stock are outstanding?
    United Therapeutics Corporation - Common Stock has 26B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.